Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SKI proto-oncogene (SKI)
- Target
- SKI
- Molecular classification
- transcription factor, nuclear proto-oncogene, transcriptional co-repressor, TGF-beta pathway repressor
01
Overview
SKI proto-oncogene encodes a nuclear protein that acts as a transcriptional co-repressor, primarily regulating the transforming growth factor-beta (TGF-beta) signaling pathway by interacting with Smad proteins and suppressing the transcription of TGF-beta-responsive genes. The protein is found in many tissues, controls processes such as cell proliferation, apoptosis, and differentiation, and is active during development and tissue homeostasis. Overexpression or mutation of SKI is associated with a variety of cancers and congenital diseases; functionally, SKI disrupts normal cellular control by interfering with growth-inhibitory signaling, contributing to oncogenesis and disease progression.
- Other names
- proto-oncogene c-Skiski oncogeneski oncoproteinSloan-Kettering Institute proto-oncogenev-ski avian sarcoma viral oncogene homologSKVSGSSKI_HUMANv-ski sarcoma viral oncogene homolog (avian)SnoN family
02
Mechanism of action
Mechanisms for potential drugs targeting SKI would include inhibition of SKI expression or activity, restoration of TGF-beta signaling, or disruption of SKI-Smads interaction to reactivate tumor suppressive signaling
03
Biological functions
Negative regulation of transforming growth factor-beta (TGF-beta) signalingCell proliferationApoptosisCell differentiationCell cycle regulationDevelopmental fate specificationsHematopoiesis regulation
04
Disease associations
Cancer (especially esophageal squamous cell carcinoma, cervical cancer, melanoma, myeloid leukemia, myeloproliferative disease)Shprintzen-Goldberg syndrome (genetic disorder with skeletal and neurological features)Tumor progression
05
Safety considerations
Challenges include off-target effects due to SKI's role in normal tissue development and hematopoiesis, possible developmental toxicity, and adverse events related to immune and transformation processesModulating TGF-beta signaling can have broad pleiotropic effects including unwanted stimulation of fibrosis or altered immune responses
06
Interacting drugs
There are currently no clinically approved drugs that directly target SKI; it is not yet a validated therapeutic target but several studies are ongoing investigating indirect modulation via TGF-beta signaling and other pathways
07
Biomarkers
High SKI expression in tumors (especially melanomas, esophageal carcinoma, cervical cancer, leukemias)Genetic mutations in SKI in Shprintzen-Goldberg syndrome
Beyond the preview
Go deeper on SKI proto-oncogene (SKI).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKI proto-oncogene (SKI).